Clinical Trial

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 26, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-05.
Status change: Recruiting → Active, Not Recruiting 2025-12-19
Trial Details
NCT Number NCT07291284
Lead Sponsor Longbio Pharma
Conditions Seasonal Allergic Rhinitis
Enrollment 546 participants
Start Date 2024-08-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-26